ReviewBiomedicines2022
Chronic Kidney Disease in Boys with Posterior Urethral Valves-Pathogenesis, Prognosis and Management.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Fetal bladder rupture in posterior urethral valves: a clinically relevant complication or a protective pop-off mechanism.Frontiers in pediatrics · 2026Pooled it
- Interpretable machine learning model for predicting kidney failure among CAKUT children in multicenter large-scale study.NPJ digital medicine · 2026Article
- Delayed Diagnosis of Posterior Urethral Valves in a 14-Year-Old Adolescent.Reports (MDPI) · 2026Article
- Post fulguration renal & bladder status (RBS grading) in prognostication of posterior urethral valves.Pediatric surgery international · 2026Article
- Posterior urethral valves: Clinical audits of presentation, diagnostic and therapeutic intervention in a nigerian teaching hospital.International urology and nephrology · 2025Article
- Long-Term Kidney Outcomes in Children with Posterior Urethral Valves: A Population-Based Cohort Study.Journal of the American Society of Nephrology : JASN · 2024Article
- Article
- Congenital anomalies of the kidney and urinary tract: defining risk factors of disease progression and determinants of outcomes.Pediatric nephrology (Berlin, Germany) · 2023Review
- Implementation of a standardized clinical pathway in a dedicated posterior urethral valves clinic: short-term outcomes.Pediatric nephrology (Berlin, Germany) · 2023Article
- Predicting outcomes in children with congenital anomalies of the kidney and urinary tract.Pediatric nephrology (Berlin, Germany) · 2023Article
- Mechanical Ablation of the Posterior Urethral Valve Omitting Thermal Energy: A Brief Report.Iranian journal of medical sciences · 2023Article
- Nadir creatinine as a predictor of renal outcomes in PUVs: A systematic review and meta-analysis.Frontiers in pediatrics · 2023Review
- High Resistance to Antibiotics Recommended in Standard Treatment Guidelines in Ghana: A Cross-Sectional Study of Antimicrobial Resistance Patterns in Patients with Urinary Tract Infections between 2017-2021.International journal of environmental research and public health · 2022Article
- Posterior urethral valves: Role of prenatal diagnosis and long-term management of bladder function; a single center point of view and review of literature.Frontiers in pediatrics · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Posterior urethral valves (PUV) are the most common form of lower urinary tract obstructions (LUTO). The valves can be surgically corrected postnatally; however, the impairment of kidney and bladder development is irreversible and has lifelong implications. Chronic kidney disease (CKD) and bladder dysfunction are frequent problems. Approximately 20% of PUV patients will reach end-stage kidney disease (ESKD). The subvesical obstruction in PUV leads to muscular hypertrophy and fibrotic remodelling in the bladder, which both impair its function. Kidney development is disturbed and results in dysplasia, hypoplasia, inflammation and renal fibrosis, which are hallmarks of CKD. The prognoses of PUV patients are based on prenatal and postnatal parameters. Prenatal parameters include signs of renal hypodysplasia in the analysis of fetal urine. Postnatally, the most robust predictor of PUV is the nadir serum creatinine after valve ablation. A value that is below 0.4 mg/dl implies a very low risk for ESKD, whereas a value above 0.85 mg/dl indicates a high risk for ESKD. In addition, bladder dysfunction and renal dysplasia point towards an unbeneficial kidney outcome. Experimental urinary markers such as MCP-1 and TGF-β, as well as microalbuminuria, indicate progression to CKD. Until now, prenatal intervention may improve survival but yields no renal benefit. The management of PUV patients includes control of bladder dysfunction and CKD treatment to slow down progression by controlling hypertension, proteinuria and infections. In kidney transplantation, aggressive bladder management is essential to ensure optimal graft survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.